Professor Lee Jordan

Honorary Professor (School of Medicine, University of Dundee), Consultant Cellular (Breast) Pathologist (NHS Tayside)

School of Medicine

On this page




+44 (0)1382 633944


Google Scholar


Professor Lee Jordan studied Medicine at the University of Edinburgh between 1991 and 1997. He also received a Medical Research Council Scholarship to study for an intercalated degree and graduated with a first class honours in Genetics (B.Sc.(Hons)) in 1996. Completion of his primary medical degree (M.B.,Ch.B.) followed in 1997.

Following clinical posts in Edinburgh and Dundee, Prof. Jordan embarked upon his cellular pathology training in Edinburgh and became a Clinical Lecturer at the University of Edinburgh. Following achievement of the M.R.C.Path by examination, he spent a sabbatical at the University of Chicago (2003), subsequently completing training in 2004 and later receiving the F.R.C.Path qualification.

Prof. Jordan was then appointed as a Consultant Cellular Pathologist with a specialist interest in Breast Pathology by NHS Tayside in 2004. He was also appointed as an Honorary Senior Clinical Teacher at that time and was promoted to an Honorary Senior Clinical Lecturer in 2011.

During his substantive career, Prof. Jordan has been the Clinical Lead for NHS Tayside Pathology (2007-2013), the Clinical Lead for the Scottish (Cellular) Pathology Network (2013-2016), interim Clinical Director for Specialist Services (2018) and was the Associate Medical Director for the Patient Access & Assurance Clinical Care Division of NHS Tayside (2018-2020). He then returned to full time clinical service to support the NHS Tayside breast cancer multi-disciplinary team through a period of staffing shortage, becoming the Lead Consultant for Breast Pathology. Prof. Jordan continues to provide this support to date. Previously, he was also the Speciality Adviser to the Scottish Chief Medical Officer for Cellular Pathology (2013-2020) and he is an accredited representative of the British Medical Association.

His research interests pertain to the pathological aspects of breast cancer and he conducts collaborative translational research alongside clinical trials activity and correlative studies with other imaging modalities including radiological imaging and computational imaging.

In 2022, Prof. Jordan was promoted to an Honorary Professorship, receiving an Honorary Chair within the University of Dundee School of Medicine.

Work for Local Bodies

NHS Tayside

  • Lead Consultant for Breast Pathology - 2020 to date
  • North Cancer Alliance/Scottish Cancer Network liaison regarding Breast Pathology Services - 2020 to date
  • Member of the NHS Tayside Local Negotiating Committee (LNC) - 2021 to date
  • Deputy Clinical Lead for Cellular Pathology (Histopathology & Cytopathology) - a COVID-19 contingency - 2020
  • Associate Medical Director for Access & Assurance – 2018-2020
  • Member of the 'Clinical Alliance' Forum - 2018-2020
  • ‘Discovery Champion’ – 2016-2019
  • Interim Clinical Director for Specialist Services – 2018
  • Chair of the pilot Primary & Secondary Care Interface Group (PSCIG) – 2017
  • Clinical Lead for Cellular Pathology (Histopathology & Cytopathology) – 2007-2013
  • Invited Member of the Scottish (Cellular) Pathology Network (SPAN) – 2007-2013
  • Invited Member of the Cancer Overview Group – 2007-2013
  • Consultant Appraiser – 2007-2010
  • Lead Consultant for Histopathology and Deputy Clinical Lead for Cellular Pathology (Histopathology & Cytopathology) – 2005-2007

University of Dundee

  • Liaison on behalf of NHS Tayside Medical Director & Chief Executive - 2018-2020
  • Invited Member of the Tayside Tissue Bank (now Tayside Biorepository) Access Committee – 2007-2018
  • Invited Member of the Tayside Tissue Bank (now Tayside Biorepository) Management Committee – 2010-2016
  • Invited member of the Cancer Informatics DECIPHER and Demonstrator project – 2011-2013
  • Liaison with the Breast Cancer Campaign* Tissue Bank (the first national biobank for human breast tissue) - 2009-2015
  • Member of the National Breast Cancer Campaign* Tissue Bank Operations Group – 2009-2011
  • Teaching contributions to the undergraduate medical curriculum including the third-year reproduction module, general pathology related teaching, and BMSc. (Genetics)
  • Contributions to postgraduate teaching and training (medical and non-medical)

University of Edinburgh

  • Membership of the University of Edinburgh Senatus Academicus – 2003-2004
  • Trainee representative to the local South East Scotland Histopathology and Laboratory Medicine Training committees – 2001-2003

Work for National Bodies

British Medical Association

  • Member of the Scottish Consultants Committee – 2022 to date
  • Member of the Scottish Consultants Committee Executive – 2022 to date
  • Member of the Scottish Consultants Committee Finance Subcommittee – 2022 to date
  • BMA Representative to the Specialty Training Board for Diagnostic Specialties (NHS Education for Scotland) – 2022 to date

Scottish Government Healthcare and Social Care Directorate

  • Scottish Chief Medical Officer’s (CMO) Specialty Adviser for Cellular Pathology – 2013-2020
  • Invited Member of the Scottish Medical and Scientific Advisory Committee (SMASAC) – 2013-2016

NHS Scotland National Specialist Services – National Services Division

  • NHS Tayside Representative to the National Specialist Services Committee - 2018-2019
  • Lead Clinician for the Scottish (Cellular) Pathology Network (SPAN) – 2013-2016
  • Invited Member of the Molecular Pathology Consortium Steering Group – 2013-2016
  • Invited Member of the Diagnostics Steering Group – 2013-2016
  • Invited Member of the Molecular Pathology Evaluation Panel – 2012-2013
  • Invited member of the Scotland & Northern Ireland EQA Scheme Management Committee – 2006-2008

Breast Cancer Now* Tissue Bank

  • Grant holder and co-creator – 2009-2015
  • Member of the Tissue Bank Operations Group – 2009-2011
  • Member of the Access Committee – 2011-2015

Royal College of Pathologists

  • Elected Member of the Scottish Regional Council – 2005-2008
  • Scottish trainee representative to the Trainee Advisory Committee (TAC) – 2001-2003
  • TAC Representative to the Specialty Advisory Committee on Histopathology – 2001-2003
  • TAC Representative to the Scottish Regional Council – 2001-2003

Work for International Bodies

  • University of Chicago & The American Association of Pathologists’ Assistants – Invited Lecture and Workshop – 2004
  • Visiting Fellow, University of Chicago – 2003

Other items

  • Peer review for scientific journals; local/national/international clinical trials work
  • (*'Breast Cancer Campaign' merged with 'Breakthrough Breast Cancer' to become 'Breast Cancer NOW' in 2015)


Professor Lee Jordan is a full-time consultant, and all research is carried out in addition to his clinical, administrative and leadership activities.

He has published scientific works that have been cited more than 5,800 times, 3,200 of these citations were in the past five years.

Google Scholar:
ALL - H-Index: 37 / i10 index: 68 / Citations: 5,830.
Since 2017 - H-Index: 28 / i10 index / 52 / Citations: 3,242.
Accessed 16/11/2022 

He has been awarded grants totalling more than £10 million.

His research has been presented nationally and internationally at numerous scientific meetings including:

  • American Society of Clinical Oncology
  • American Association for Cancer Research
  • American Society of Human Genetics
  • Association of Breast Surgery
  • Association of Physicians of Great Britain and Ireland
  • British Breast Group
  • British Society of Breast Radiology
  • European Breast Cancer Conference
  • European Congress of Radiology
  • European Conference on Mathematical and Theoretical Biology / Society for Mathematical Biology
  • European, Middle Eastern & African Society for Biopreservation & Biobanking
  • European Organisation for Research and Treatment of Cancer
  • European Society for Medical Oncology
  • IMPAKT Breast Cancer Conference
  • Institute of Electrical and Electronics Engineers
  • International Society for Biological and Environmental Repositories
  • Medical Image Computing and Computer Assisted Intervention
  • Medical Imaging Understanding and Analysis
  • National Cancer Institutes/National Institutes of Health
  • National Cancer Research Institute
  • Pathological Society of Great Britain & Ireland
  • Radiological Society of North America
  • Royal College of Radiologists Breast Group
  • The San Antonio Breast Cancer Symposium
  • Society of Academic & Research Surgery
  • Society for Mathematical Biology

Only the most ten most recent peer-reviewed articles published (as of November 2022) are presented:

  1. Nguyen Van Long F, Lardy-Cleaud A, Carène D, Rossoni C, FCatez F, Rollet P, Pion N, Monchiet D, Agathe Dolbeau A, Martin M, Simioni V, Bray S, Le Beherec D, Mosele F, Bouakka I, Colombe-Vermorel A, Odeyer L, Lavergne E, Diot A, Jordan LB, Thompson AM, Jamen F, Dubois T, Chabaud S, Michiels S, Treilleux I, Bourdon JC, Pérol D, Puisieux A, Fabrice A, Diaz JJ, Marcel V. Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer.  BMC Cancer 2022; 526.
  2. Quinlan PR, Figeuredo G, Mongan N, Jordan LB, Bray SE, Sreseli R, Ashfield A, Mitsch J;  Van Den Ljssel J; Thompson AM, Quinlan RA. Cluster analyses of the TCGA and a TMA dataset using the coexpression of HSP27 and CRYAB improves alignment with clinical-pathological parameters of breast cancer and suggests different epichaperome influences for each sHSP. Cell Stress & Chaperones 2022; 27(2): 177 - 188. doi: 10.1007/s12192-022-01258-0.
  3. Wang H, Donnan P, Macaskill EJ, Jordan LB, Thompson AM, Evans AJ. A pre-operative prognostic model predicting all cause and cause specific mortality for women presenting with invasive breast cancer. The Breast 2022; 61: 11 - 21. doi: 10.1016/j.breast.2021.12.002
  4. Evans AJ, Sim YT, Lawson Brooke, Macaskill EJ, Jordan LB, Thompson AM. The value of prognostic ultrasound features of breast cancer in different molecular subtypes with a focus on triple negative disease. Breast Cancer 2022; 29(2): 296 - 301. doi: 10.1007/s12282-021-01311-3.
  5. Evans AJ, Sim YT, Whelehan P, Savaridas S, Jordan LB, Thompson AM. Are baseline mammographic and ultrasound features associated with metastasis free survival in women receiving neoadjuvant chemotherapy for invasive breast cancer? Eur J Radio 2021; 109790. doi: 10.1016/j.ejrad.2021.109790.
  6. Marcel V, Kielbassa J, Marchand V, Natchiar KS, Paraqindes H, Nguyen Van Long F, Ayadi L, Bourguignon-Igel V, Lo Monaco P, Monchiet D, Scott V, Tonon L, Bray SE, Diot A, Jordan LB, Thompson AM, Bourdon JC, Dubois T, André F, Catez F, Puisieux A, Motorin Y, Klaholz BP, Viari A, Diaz JJ. Ribosomal RNA 2′ O-methylation as a novel layer of inter-tumour heterogeneity in breast cancer. NAR Cancer 2020; 2(4): zcaa036. doi: 10.1093/narcan/zcaa036.
  7. Liu Y, Nekulova M, Nenutil R, Horakova I, Appleyard MV, Murrary K, Holcakova J, Galoczova M, Quinlan P, Jordan LB, Purdie CA, Vojtesek B, Thompson AM, Coates PJ. ΔNp63/p40 correlates with the location and phenotype of basal/mesenchymal cancer stem-like cells in human ER+ and HER2+ breast cancers. J Pathol Clin Res 2020; 6(1): 83 - 93. doi: 10.1002/cjp2.149.
  8. Evans A, Whelehan P, Thompson A, Purdie CA, Jordan LB, Macaskill J, Waugh S, Fuller-Pace F, Brauer K, Vinnicombe S. Prediction of pathological complete response to neoadjuvant chemotherapy for primary breast cancer comparing interim ultrasound, shear wave elastography and MRI. Ultraschall in Med 2018; 39(4): 422-431. doi: 10.1055/s-0043-111589.
  9. Yeap PM, Evans A, Purdie CA, Jordan LB, Vinnicombe SJ. A comparison of the imaging features of pleomorphic and classical invasive lobular carcinoma. Breast Cancer Res Treat 2018; 172(2): 381 - 389. doi: 10.1007/s10549-018-4914-8.
  10. Ahmeidat H, Purdie C, Jordan L, Fleming D, McCullough J, Evans A. Non-histopathological parameters associated with upgrade of breast tumours yielding a core biopsy report of histological grade 2 ductal no special type to grade 3 on excision. Eur J Surg Oncol 2018; 44(11): 1720 -1 724. doi: 10.1016/j.ejso.2018.07.002).



He was invited to lecture to the American Association of Pathologists’ Assistants in Chicago in 2004 regarding the UK experience of autopsy pathology in light of the then recent organ retention scandal.


He has been invited to lecture both medical and non-medical staff across Scotland in relation to his national roles and also for post-graduate training. He has also contributed to the examination work of the R.C.Path.


He has contributed to local undergraduate medical education in relation to general pathology, cardiovascular pathology, breast pathology and human genetics. He has also provided post-graduate teaching and mentoring for non-medical staff undergoing medical role extension training and has provided secondary level supervision for M.D. and Ph.D. students.

PhD Supervision

Ph. D. - secondary supervision of the following:

Akbar S. Tumour localisation in histopathology images. 2015.

Ph.D. - tertiary supervision of the following:

Amaral, T. Analysis of breast tissue microarray spots. 2010.

M.D. - secondary supervision of the following:

Sreseli, R. NF-kB complex activation and association of Alpha B-crystallin and vimentin with poor prognosis in primary breast cancer. 2012.